Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Adagene ( (ADAG) ) has provided an update.
On August 12, 2025, Adagene Inc. announced its financial results for the first half of 2025, highlighting significant advancements in its clinical programs and strategic partnerships. The company reported promising data from its Phase 1b/2 trial of ADG126 in combination with Merck’s KEYTRUDA® for microsatellite stable colorectal cancer, showing a median overall survival of 19.4 months in the 10 mg/kg dose cohort. Additionally, Adagene has aligned with the FDA on the design elements for upcoming Phase 2 and Phase 3 trials, with plans to begin patient enrollment in the second half of 2025. The company also secured a strategic investment of up to $25 million from Sanofi, extending its cash runway into 2027, and entered into a partnership with ConjugateBio for the development of bispecific ADCs.
The most recent analyst rating on (ADAG) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Adagene stock, see the ADAG Stock Forecast page.
Spark’s Take on ADAG Stock
According to Spark, TipRanks’ AI Analyst, ADAG is a Neutral.
Adagene’s overall stock score is primarily impacted by its poor financial performance, with significant losses and negative cash flows. While technical analysis shows some positive momentum, the valuation remains challenging due to negative earnings. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ADAG stock, click here.
More about Adagene
Adagene Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based therapies. The company operates in the biotechnology industry and is known for its platform-driven approach to developing therapies, particularly in the area of antibody engineering and novel therapeutic solutions.
Average Trading Volume: 74,740
Technical Sentiment Signal: Hold
Current Market Cap: $107.9M
For detailed information about ADAG stock, go to TipRanks’ Stock Analysis page.